Phase I Trial Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Solid Tumors Including But Not Limited to NSCLC or HCC
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2019
At a glance
- Drugs IMA-202 (Primary)
- Indications Liver cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms ACTengine
- Sponsors Immatics US
- 02 Jan 2019 Planned initiation date changed from 1 Mar 2018 to 1 Mar 2019.
- 01 Aug 2018 Status changed from not yet recruiting to recruiting.
- 27 Feb 2018 New trial record